Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says

Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet